近些年晓折，多發(fā)性骨髓瘤上市了新藥硼替佐米和來(lái)那度胺惑朦，讓醫(yī)生有了更多選擇，同時(shí)不斷有新的臨床研究數(shù)據(jù)出現(xiàn)漓概，讓醫(yī)生選擇最優(yōu)方案也犯了難。不過(guò)病梢，來(lái)那度胺加地塞米松還是基礎(chǔ)胃珍。楊森的Darzalex (daratumumab)準(zhǔn)備搶風(fēng)頭了。本屆EHA大會(huì)上楊森的Darzalex (daratumumab)的三期臨床研究（CASTOR）顯示在三線治療蜓陌，Darzalex加硼替佐米加地塞米松比硼替佐米加地塞米松觅彰，減少疾病進(jìn)展或死亡風(fēng)險(xiǎn)百分之61。這方案也夠貴钮热，好像楊森喜歡整豪華方案填抬，如硼替佐米加脂質(zhì)體阿霉素等。
原文如下
KOL Views: How and how quickly might Darzalex move upstream in multiple myeloma practice patterns – and what may stand in its way?
(Ref: KOL Views Desk) June 14th, 2016 By: Michael Flanagan
New drugs for multiple myeloma (MM) have been coming to market left and right over the past few years, adding new layers of complexity to established practice patterns. A good problem to have, to be sure, but the steady flow of clinical data has made the task of ensuring optimal treatment for patients all the more difficult for physicians.
Despite recent changes, one thing that has remained consistent has been the use of Celgene’s Revlimid (lenalidomide) plus dexamethasone as the backbone of the increasingly complicated combinations that have become commonplace in MM.
Darzalex (daratumumab) from Johnson & Johnson and Genmab is one of the fresh combatants in the MM arena, though like other new agents it has been relegated largely to use as part of in later-line therapy. That may soon change, however, based on a pair of readouts presented at this month’s annual ASCO meeting.
Specifically, data from the Phase III CASTOR trial showed Darzalex reduced the risk of disease progression or death by 61 percent when added to Velcade (bortezomib) and dexamethasone versus the doublet in third-line patients. In addition, data from the Phase III POLLUX trial showed the anti-CD38 mAb reduced the risk of disease progression or death by 63 percent when added to Revlimid plus dexamethasone versus the doublet in second-line patients. (See ViewPoints: Darzalex hits second home run, but experts cautious on pricing of combination therapies in myeloma.)
The readouts are likely to pave the way for Darzalex to move rapidly upstream into earlier lines of therapy for MM, though the complex and ever-evolving nature of the treatment algorithm raises a lot of questions.
